The GMP Insider
Similar topics: pharmaceutical and beyond
Science
Pharmaceutical Executive
by Pharmaceutical Executive Podcast
Today: #87 in Science, Japan on our combined chart.
Share this ranking
Claiming needs an RSS feed. Contact us.
Chart positions today · Japan
Not on the United States charts we track today.
Not on the United Kingdom charts we track today.
Not on the Canada charts we track today.
Not on the Australia charts we track today.
Not on the Germany charts we track today.
Not on the Brazil charts we track today.
Not on the Mexico charts we track today.
Not on the New Zealand charts we track today.
Not on the Ireland charts we track today.
Not on the India charts we track today.
Not on the Philippines charts we track today.
Not on the South Africa charts we track today.
If you like Pharmaceutical Executive, try…
20 The Countdown Magazine
Also in Science
» Divine Intervention Podcasts
Also in Science
Interviews 02
Also in Science
Security, Spoken
Also in Science
Ranking history · Japan
History builds daily. We started tracking this show on the Science, Japan chart recently, so the trend line appears after a second day of data.
View as table
| Date | Combined Rank | Apple Podcasts |
|---|---|---|
| Oct 12 | #87 | #86 |
Latest episodes
-
Pharmaceutical Executive Daily: FDA Approves Tecentriq
October 9, 2026 · 3 minThe FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains…
-
Pharmaceutical Executive Daily: Ultragenyx Sells Rare Pediatric Disease Priority Review Voucher
October 8, 2026 · 3 minUltragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for $1.65 billion, and Peter Young surveys a steadying biopharma outlook.
-
Pharmaceutical Executive Daily: FDA Approves Tukysa Plus Trastuzumab and Pertuzumab
October 7, 2026 · 3 minCaribou Biosciences discontinues its two allogeneic CAR-T programs, Kamal Biswas makes the case for continuous quality management maturity, and FDA approves Pfizer’s Tukysa as a first-line maintenance therapy in HER2-positive breast cancer.
-
Pharmaceutical Executive Daily: What HCP Engagement Actually Looks Like
October 6, 2026 · 3 minShionogi, Gate Bioscience, and Alector post a trio of new deals, Rajul Jain makes the case for social listening as a medical affairs strategic tool, and Doceree's Vijay Adapala argues that HCP engagement is a systems-design problem, not a…
-
AI and Patient Recruitment: Can Predictive Promise Drive True Transformation?
October 6, 2026 · 27 minCan artificial intelligence help turn what many believe is clinical development’s biggest variable — and most prevailing bottleneck — into a more predictable process? In this episode of the Pharm Exec podcast, Matt Walz, CEO of Trialbee, a…
Show 7 more episodesShow fewer episodes
-
Pharmaceutical Executive Daily: CSL & Alentis Enter $1.6 Billion Global Partnership
October 5, 2026 · 3 minJewel Jones warns that pharma catches patient disengagement too late, CSL and Alentis Therapeutics join Jiangsu Nhwa and Somnivera in a day of new licensing deals, and Corxel's Bo Liang calls GLP-1's leap to bariatric-surgery-level…
-
Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909
October 2, 2026 · 3 minFoghorn Therapeutics and Eli Lilly discontinue their SMARCA2 degrader program, Novartis licenses Abogen's autoimmune mRNA therapy while AstraZeneca, Daiichi Sankyo, and Summit Therapeutics team up on a breast cancer combination trial, and…
-
Pharmaceutical Executive Daily: FDA Approves Expanded Indication for Camzyos
October 1, 2026 · 3 minRegeneron and Sanofi expand their antibody alliance with four new drug candidates, FDA approves Camzyos for adolescents with obstructive hypertrophic cardiomyopathy, and Michael Abrams questions digital health's savings claims to employers.
-
Pharmaceutical Executive Daily: Peptide Ruling Stalls
September 30, 2026 · 3 minNovo Nordisk data show real-world weight loss after switching to its oral semaglutide pill, FDA's peptide rulemaking stalls while its enforcement arm targets compounded peptide sellers, and Avi Pardo flags a compliance blind spot in field…
-
A Leadership Call to Action for Biotech
September 30, 2026 · 36 minIn this episode of Leading Edge with Ken Banta, Jeremy Levin, D.Phil, MB BChir, co-founder and executive chairman of Ovid Therapeutics, joins Banta, The Vanguard Network founder and CEO, for a wide-ranging and candid discussion on the…
-
Pharmaceutical Executive Daily: Fabrice Chouraqui Steps Down as CEO of Pharming
September 29, 2026 · 3 minNew U.S. guidance carves out tariff exemptions for specialty pharmaceuticals, Pharming's Fabrice Chouraqui steps down as CEO amid a board rift, and a dealmaking roundup covers Hengrui Pharma's licensing agreement with Novo Nordisk and…
-
Pharmaceutical Executive Daily: Merck Acquires SPR2015 in $2.13 Billion Licensing Deal
September 28, 2026 · 3 minMerck licenses a preclinical KRAS G12D inhibitor from SciBrunch, FDA approves Olumiant, Juvmo, and Atebrioz across three separate indications, and Matthew Montes de Oca makes the case for compounding pharmacies to set their own safety…
About the show
The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.